Baseline Hemostatic Biomarker Assessment Identifies Breast Cancer Patients at High Risk for Venous Thromboembolism During Chemotherapy.

Publisher: MDPI Country of Publication: Switzerland NLM ID: 101526829 Publication Model: Electronic Cited Medium: Print ISSN: 2072-6694 (Print) Linking ISSN: 20726694 NLM ISO Abbreviation: Cancers (Basel) Subsets: PubMed not MEDLINE

Original Publication: Basel, Switzerland : MDPI

(1) Background: The presence of metastatic disease significantly increases the risk of venous thromboembolism (VTE) in breast cancer, particularly during chemotherapy. Although not categorized as a highly thrombogenic malignancy, the elevated global prevalence of this cancer places a substantial number of patients at risk of thrombosis, which cannot yet be accurately predicted by validated risk assessment models (RAMs), highlighting the need for a dedicated model. (2) Aim: This study aims to develop a RAM for VTE in newly diagnosed metastatic breast cancer patients enrolled in a prospective, observational, and multicenter study. (3) Methods: A cohort of 189 patients beginning antitumor therapy were enrolled and prospectively monitored for VTE and mortality. Blood samples collected at enrollment were tested for D-dimer, fibrinogen, FVIII, prothrombin fragment 1 + 2 (F1 + 2), and thrombin generation (TG). Competing risk analyses were performed to identify significant predictors. (4) Results: Within one year, the cumulative incidences of VTE and mortality were 7.0% and 12%, respectively. Univariable analysis identified high Ki-67, D-dimer, FVIII, fibrinogen, and TG levels, along with low hemoglobin levels, as independent predictors of VTE. Only Ki-67, fibrinogen, FVIII, and hemoglobin were retained as significant predictors in multivariable analysis. These variables were further examined by multiple linear regression, which revealed Ki-67 and fibrinogen as the most significant parameters. A continuous RAM was then developed based on Ki-67 and fibrinogen (c-statistics 0.78), categorizing patients into low-risk and high-risk groups for VTE (2% vs. 13%; SHR 3.6, p = 0.018). This stratification could not be achieved using currently validated models for VTE risk. (5) Conclusions: We developed an accurate RAM for VTE that enables the identification of metastatic breast cancer patients at high risk for VTE, which supports clinicians in personalized thromboprophylaxis strategies if externally validated.

J Adv Nurs. 2021 Jan;77(1):473-483. (PMID: 33159325)
CA Cancer J Clin. 2024 May-Jun;74(3):229-263. (PMID: 38572751)
J Clin Oncol. 1991 Feb;9(2):286-94. (PMID: 1988575)
Thromb Haemost. 2014 Sep 2;112(3):486-94. (PMID: 24964786)
Cancer Med. 2020 Mar;9(5):1768-1778. (PMID: 31962001)
Anticancer Res. 2011 Jun;31(6):2383-8. (PMID: 21737669)
Arterioscler Thromb Vasc Biol. 2009 Dec;29(12):2176-81. (PMID: 19778945)
JAMA. 2008 Nov 19;300(19):2277-85. (PMID: 19017914)
Blood. 2008 May 15;111(10):4902-7. (PMID: 18216292)
Cancers (Basel). 2022 Feb 16;14(4):. (PMID: 35205736)
Breast. 2025 Feb;79:103851. (PMID: 39580931)
Cancer. 2009 Oct 1;115(19):4442-9. (PMID: 19569248)
Thromb Res. 2012 Apr;129 Suppl 1:S132-6. (PMID: 22682124)
J Thromb Haemost. 2020 Jan;18(1):162-168. (PMID: 31479568)
J Thromb Haemost. 2012 Dec;10(12):2599-601. (PMID: 23362524)
Cancers (Basel). 2021 Sep 03;13(17):. (PMID: 34503265)
Thromb Res. 2024 Feb;234:120-133. (PMID: 38215613)
Blood Adv. 2021 Feb 23;5(4):927-974. (PMID: 33570602)
J Clin Oncol. 2007 Jan 1;25(1):70-6. (PMID: 17194906)
J Clin Oncol. 2015 Jan 10;33(2):141-8. (PMID: 25185099)
Blood. 2021 Apr 8;137(14):1959-1969. (PMID: 33171494)
Signal Transduct Target Ther. 2025 Feb 19;10(1):49. (PMID: 39966355)
Chin Clin Oncol. 2012 Dec;1(2):19. (PMID: 25841397)
Cancer Causes Control. 2016 May;27(5):695-707. (PMID: 27059219)
Crit Rev Oncol Hematol. 2020 Sep;153:102988. (PMID: 32599374)
Thromb Res. 2022 May;213 Suppl 1:S58-S65. (PMID: 36210562)
Thromb Res. 2015 Feb;135 Suppl 1:S8-S11. (PMID: 25903541)
J Clin Oncol. 2011 May 20;29(15):2099-103. (PMID: 21464402)
Lancet. 2024 May 11;403(10439):1895-1950. (PMID: 38636533)
Thromb Res. 2011 Oct;128(4):368-74. (PMID: 21458031)
Cancer. 2017 Feb 1;123(3):468-475. (PMID: 27727456)
Cancer Treat Rev. 2022 Jan;102:102322. (PMID: 34922151)
BMC Cancer. 2014 Dec 22;14:991. (PMID: 25535397)
Cancer. 1984 Oct 1;54(7):1264-8. (PMID: 6547874)
Ann Oncol. 2023 May;34(5):452-467. (PMID: 36638869)
J Thromb Haemost. 2008 Jan;6(1):125-31. (PMID: 17988231)
Haematologica. 2020 Jun;105(6):1704-1711. (PMID: 31558668)
J Thromb Haemost. 2020 Aug;18(8):1940-1951. (PMID: 32336010)
Lancet Reg Health Eur. 2023 Sep 28;34:100739. (PMID: 37809052)
Clin Appl Thromb Hemost. 2022 Jan-Dec;28:10760296221095558. (PMID: 35549519)
JAMA Oncol. 2024 Jan 1;10(1):71-78. (PMID: 37943547)
Front Oncol. 2022 Jul 19;12:772726. (PMID: 35928882)
Thromb Res. 2015 Dec;136(6):1120-5. (PMID: 26475410)
BMC Cancer. 2017 Nov 10;17(1):747. (PMID: 29126386)
Cells. 2023 Jul 29;12(15):. (PMID: 37566045)
Lancet Oncol. 2022 Jul;23(7):e334-e347. (PMID: 35772465)
Thromb Res. 2022 May;213 Suppl 1:S8-S15. (PMID: 36210566)
Med Oncol. 2018 Apr 3;35(5):63. (PMID: 29616356)
Br J Cancer. 2008 Oct 7;99(7):1000-6. (PMID: 18766191)
Thromb Res. 2016 Apr;140 Suppl 1:S55-9. (PMID: 27067979)
Lancet Oncol. 2010 Feb;11(2):174-83. (PMID: 20152769)
Lancet Haematol. 2018 Jul;5(7):e289-e298. (PMID: 29885940)
Cancers (Basel). 2022 Sep 06;14(18):. (PMID: 36139507)
JNCI Cancer Spectr. 2023 Aug 31;7(5):. (PMID: 37567612)
Blood. 2016 Feb 18;127(7):849-57; quiz 953. (PMID: 26574606)
J Clin Oncol. 2012 Dec 10;30(35):4416-26. (PMID: 23150697)
Oncologist. 2017 Oct;22(10):1222-1231. (PMID: 28550032)
N Engl J Med. 1988 Feb 18;318(7):404-7. (PMID: 3340118)
Blood. 2008 Nov 15;112(10):4061-8. (PMID: 18768782)
Breast Cancer. 2025 Jan;32(1):154-165. (PMID: 39549222)
TH Open. 2021 Feb 10;5(1):e56-e65. (PMID: 33585786)
Thromb Res. 2008;121(5):637-45. (PMID: 17692905)
Blood Coagul Fibrinolysis. 2021 Sep 1;32(6):373-381. (PMID: 33973894)
J Thromb Haemost. 2020 Sep;18(9):2220-2231. (PMID: 32397009)
Cancers (Basel). 2023 Sep 15;15(18):. (PMID: 37760562)
Cancers (Basel). 2020 Feb 29;12(3):. (PMID: 32121387)

12237 Associazione Italiana Ricerca sul Cancro; ARTET001 Fondazione ARTET Onlus; N.A. Fondazione Banca Popolare di Bergamo

Keywords: D-dimer; Ki-67; fibrinogen; hemostatic biomarkers; hypercoagulability; metastatic breast cancer; mortality; venous thromboembolism

Date Created: 20250828 Date Completed: 20250914 Latest Revision: 20250914

20250915

PMC12384613

10.3390/cancers17162712

40867341